Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 22,850 | 26,250 | 28,695 | 32,370 | 21,607 |
| TOTAL | $23,576 | $26,484 | $29,560 | $33,069 | $22,521 |
| Non-Current Assets | |||||
| PPE Net | 82 | 87 | 92 | 90 | 88 |
| Other Non-Current Assets | 322 | 323 | 312 | 41 | 41 |
| TOTAL | $403 | $410 | $405 | $131 | $129 |
| Total Assets | $23,980 | $26,894 | $29,965 | $33,200 | $22,650 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,352 | 1,154 | 964 | 1,318 | 1,670 |
| Accrued Expenses | 2,009 | 2,482 | 2,079 | 1,498 | 2,186 |
| TOTAL | $3,361 | $3,636 | $3,094 | $2,965 | $4,386 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 51 | 148 | 529 |
| Other Non-Current Liabilities | 1,311 | 1,311 | 1,311 | 1,311 | 1,311 |
| TOTAL | $1,311 | $1,311 | $1,311 | $1,311 | $1,311 |
| Total Liabilities | $4,672 | $4,947 | $4,405 | $4,276 | $5,697 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5,492 | 5,435 | 5,432 | 5,430 | 5,430 |
| Common Shares | 6 | 5 | 5 | 5 | 4 |
| Retained earnings | -321,042 | -318,147 | -314,363 | -310,893 | -308,083 |
| Other shareholders' equity | -10,627 | -10,605 | -10,628 | -10,626 | -10,611 |
| TOTAL | $19,308 | $21,947 | $25,559 | $28,924 | $16,954 |
| Total Liabilities And Equity | $23,980 | $26,894 | $29,965 | $33,200 | $22,650 |